Haifeng Chen
Seminars
Wednesday 29th July 2026
Breaking Barriers in In Vivo CAR-T Therapy: CD3scFv-Engineered AAV Capsids Enable Potent CAR-T Generation, Complete Tumor Eradication, and Expansion into Autoimmune Diseases
2:00 pm
- CD3scFv-engineered AAV capsids enable T-cell-specific targeting and activation of resting T cells in vivo, delivering CAR constructs via a single IV injection — bypassing leukapheresis, ex vivo manufacturing, and lymphodepletion
- Preclinical data in Raji lymphoma NSG mouse models demonstrate rapid, potent CAR-T expansion and complete tumor eradication, with superior safety from nonintegrating, episomal AAV persistence
- Platform expansion into autoimmune diseases, powered by proprietary Safety Shield (miRNA-based mRNA control) and BAC-to-AAV manufacturing technologies, positions AAVivo for broader, more accessible cell therapies
